ICON Announces Release of ADDPLAN® neo
01 Outubro 2018 - 8:00AM
Business Wire
Software provides an integrated technology
platform for adaptive clinical trials
(NASDAQ: ICLR) a global provider of drug development
services to the pharmaceutical, biotechnology and medical device
industries, today announced the release of ADDPLAN® neo, providing
an advanced validated integrated technology platform for design,
simulation and analysis of adaptive clinical trials.
The new release combines ADDPLAN® BASE, ADDPLAN® MC (for
Multiple Comparison Designs) and ADDPLAN® DF (for dose ranging and
dose finding trials using MCP-Mod methodology) modules under one
umbrella, increasing simulation speed for each application and
allowing computation of multiple projects on one, integrated robust
framework. The software has been rewritten using C programming
language to ensure efficient usage of computing resources and fast
simulation results.
Following feedback from customers, ICON enhanced the algorithms’
stability and speed and added new features such as the ability to
incorporate custom R code in the ADDPLAN® neo Dose Finding
module.
Additional ADDPLAN® neo features include:
- Every-Phase Capabilities – Strengthen
and advance study design, simulation and analysis for every phase
of drug development, including Adaptive MCP-Mod, critical for
dose-finding designs.
- Improved User Experience – A fully
validated, graphical user interface (GUI) software, ADDPLAN® neo
features a quick access to adaptive approaches across all phases of
drug development.
Andrew Garrett, EVP Scientific Operations said “With the recent
FDA announcement of its Complex Innovative Designs Pilot Meeting
Program, targeted at innovative trial designs to inform regulatory
decision making, the door is very much open for adaptive and other
types of innovative design. ADDPLAN® neo provides an integrated and
increasingly flexible solution that truly supports this innovation
agenda by providing a validated tool that helps convert theory to
practice.”
About ICON plcICON plc is a global provider of outsourced
drug development and commercialisation solutions and services to
pharmaceutical, biotechnology, medical device, and government and
public health organisations. The company specializes in the
strategic development, management and analysis of programs that
support clinical development from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 93 locations in 37 countries and has
approximately 13,675 employees.
Further information is available at
www.iconplc.com/addplanneo
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181001005399/en/
ICON Media ContactLucinda Sandon-AllumWeber Shandwick+44
(0)20 7067 0548lsandon-allum@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024